BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is proud to announce the appointment of Dr. Thomas Kindt as Chief Scientific Officer (CSO). Dr. Kindt has been a member of InNexus’ Scientific Advisory Board and was most recently Director of Intramural Research and Chief of Laboratory of Immunogenetics at the NIH in Bethesda, Maryland. Dr. Kindt replaces Dr. Kohler who remains a Consultant to the Company.